Back to News
Market Impact: 0.35
AstraZeneca's Enhertu Gets NICE Recommendation For HER2 Low Metastatic Breast Cancer
Source: Nasdaq
Healthcare & BiotechRegulation & LegislationProduct Launches
AstraZeneca and Daiichi Sankyo's Enhertu received a positive NICE recommendation for reimbursement in England for eligible patients with HER2-low metastatic disease. The recommendation expands potential patient access to the cancer therapy in England and is a positive commercial and regulatory milestone for both drugmakers.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.48
Ticker Sentiment
AZN0.65
More News
- UBS downgrades Roche stock rating to neutral on valuation concerns
- Daiichi Sankyo Q2 FY2026 slides: oncology surge drives record growth
- Amgen (AMGN) Bets on MariTide to Crack $120 Billion Obesity Market
- BTIG cuts Acumen Pharmaceuticals stock price target to $1 on trial results
- Jefferies raises West Pharmaceutical stock price target on HVP growth
- Wells Fargo raises Abbvie stock price target to $340 on pipeline